Supernus Pharmaceuticals (SUPN) Share-based Compensation (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Share-based Compensation data on file, last reported at $4.6 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 36.34% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $34.3 million, a 20.26% increase from a year earlier, with the FY2025 full-year figure at $33.1 million, up 19.08% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.6 million, down from $28.9 million in the prior quarter.
• Over the last five years, Share-based Compensation for SUPN reached as high as $28.9 million in Q4 2025 and fell as low as -$1.9 million in Q3 2023.
• Historically, Share-based Compensation has averaged $5.3 million across 5 years, with a median of $2.6 million in 2023.
• On a YoY basis, Share-based Compensation climbed as much as 9533.33% in 2023 and fell as far as 355.98% in 2023.
• Year by year, Share-based Compensation stood at $16.6 million in 2022, then sank by 111.74% to -$1.9 million in 2023, then soared by 491.79% to $7.6 million in 2024, then surged by 278.05% to $28.9 million in 2025, then plunged by 84.21% to $4.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $4.6 million in Q1 2026, $28.9 million in Q4 2025, and $811000.0 in Q3 2025.